Nordson(US:NDSN)2025-05-28 20:35Financial Performance - Sales for the second quarter of fiscal 2025 were $683 million, a 5% increase compared to $651 million in the prior year[1]. - Net income for the second quarter was $112 million, or $1.97 per diluted share, down from $118 million, or $2.05 per diluted share in the prior year[2]. - Adjusted earnings per diluted share increased by 3% to $2.42 from $2.34 in the prior year[2]. - EBITDA for the second quarter was $217 million, representing 32% of sales, up 7% from $203 million, or 31% of sales in the prior year[3]. - Total sales for the six months ended April 30, 2025, were $1,298,358 million, a slight increase of 1.1% compared to $1,283,835 million for the same period in 2024[24]. - Net income for the three months ended April 30, 2025, was $112,404 million, down from $118,217 million in the same period last year[26]. - Diluted earnings per share for the three months ended April 30, 2025, was $1.97, compared to $2.05 for the same period in 2024[30]. - The company reported total operating profit of $168,750 million for the three months ended April 30, 2025, slightly up from $168,616 million year-over-year[30]. - Adjusted net income for the six months ended April 30, 2025, was $256,423 million, compared to $262,458 million in the same period last year[30]. - Year-to-date net income is $207,056,000, an increase from $94,652,000 in the previous year, showing a significant growth of approximately 118.1%[32]. Segment Performance - Industrial Precision Solutions sales decreased by 8% to $319 million, while Medical and Fluid Solutions sales increased by 20% to $203 million[5][6]. - Advanced Technology Solutions sales increased by 18% organically, driven by demand in semiconductor and electronics markets[7]. - The Industrial Precision Solutions segment reported sales of $619,295 million, down 7.6% from $682,720 million[28]. - Medical and Fluid Solutions segment sales increased by 20.7% to $396,418 million from $328,492 million[28]. Cash Flow and Investments - Year-to-date net cash provided by operating activities is $278,292,000, compared to $294,964,000 in the same period last year, reflecting a decrease of approximately 5.7%[32]. - Year-to-date free cash flow is $240,853,000, down from $273,057,000 year-over-year, indicating a decline of about 11.8%[32]. - Free cash flow conversion for the year-to-date is 116%, compared to 146% in the same period last year, indicating a decrease of 30%[32]. - Additions to property, plant, and equipment year-to-date total $37,439,000, up from $21,907,000 in the previous year, representing an increase of approximately 70.7%[32]. Future Outlook - The company expects third quarter fiscal 2025 sales to be in the range of $710 to $750 million, with adjusted earnings forecasted between $2.55 and $2.75 per diluted share[9]. - Backlog grew approximately 5% during the quarter, indicating strong order entry trends[8]. - The Atrion acquisition continues to perform above expectations, contributing positively to the company's results[4]. - The company repurchased $85 million in shares during the quarter, maintaining a sound balance sheet[4]. Geographic Performance - Sales in the Americas decreased by 13.4% to $560,300 million from $568,440 million year-over-year[24]. - The Asia Pacific region saw a sales increase of 10.7%, reaching $397,799 million compared to $354,015 million in the previous year[24].